The effects of suppressing inflammation by tofacitinib may simultaneously improve glycaemic parameters and inflammatory markers in rheumatoid arthritis patients with comorbid type 2 diabetes: a proof-of-concept, open, prospective, clinical study.
Claudia Di MuzioIlenia Di ColaAzadeh Shariat PanahiFrancesco UrsiniAnnamaria IagnoccoRoberto GiacomelliPaola CiprianiPiero RuscittiPublished in: Arthritis research & therapy (2024)
The administration of tofacitinib in RA with T2D led to a simultaneous improvement of IR and inflammatory disease activity, inducing a "bidirectional" benefit in these patients. However, further specific designed and powered studies are warranted to entirely evaluate the metabolic effects of tofacitinib in RA patients with T2D.
Keyphrases
- rheumatoid arthritis
- disease activity
- type diabetes
- ankylosing spondylitis
- rheumatoid arthritis patients
- oxidative stress
- interstitial lung disease
- end stage renal disease
- juvenile idiopathic arthritis
- systemic lupus erythematosus
- newly diagnosed
- prognostic factors
- peritoneal dialysis
- minimally invasive
- cardiovascular disease
- patient reported outcomes
- glycemic control
- adipose tissue
- weight loss
- systemic sclerosis
- light emitting